Cargando…

Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer

The value of assessing tumor infiltrating lymphocytes (TILs) in estrogen receptor (ER) positive/human epidermal growth factor receptor type 2 (HER2) negative breast cancer has yet to be determined. In the present study, a total of 184 cases with early distant recurrence detected within 5 years follo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miyoshi, Yuichiro, Shien, Tadahiko, Ogiya, Akiko, Ishida, Naoko, Yamazaki, Kieko, Horii, Rie, Horimoto, Yoshiya, Masuda, Norikazu, Yasojima, Hiroyuki, Inao, Touko, Osako, Tomofumi, Takahashi, Masato, Tomioka, Nobumoto, Wanifuchi-Endo, Yumi, Hosoda, Mitsuchika, Doihara, Hiroyoshi, Yamashita, Hiroko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341802/ https://www.ncbi.nlm.nih.gov/pubmed/30675282 http://dx.doi.org/10.3892/ol.2018.9853

Ejemplares similares

Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence
por: Miyoshi, Yuichiro, et al.
Publicado: (2016)

Fertility preservation in breast cancer patients
por: Shien, Tadahiko, et al.
Publicado: (2013)

Effect of local surgery on outcomes of stage IV breast cancer
por: Tsukioki, Takahiro, et al.
Publicado: (2020)

The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells
por: Ikeda, Hirokuni, et al.
Publicado: (2010)

Fibroblast growth factor receptor‐1 protein expression is associated with prognosis in estrogen receptor‐positive/human epidermal growth factor receptor‐2‐negative primary breast cancer
por: Tomiguchi, Mai, et al.
Publicado: (2016)

A Case of Carcinoma Showing Thymus-Like Differentiation with a Rapidly Lethal Course
por: Nogami, Tomohiro, et al.
Publicado: (2014)

A Radial Sclerosing Lesion Mimicking Breast Cancer on Mammography in a Young Woman
por: Furukawa, Masashi, et al.
Publicado: (2012)

Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples
por: Iwamoto, Takayuki, et al.
Publicado: (2019)

Influences of preoperative metformin on immunological factors in early breast cancer
por: Tsukioki, Takahiro, et al.
Publicado: (2020)

Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan
por: OSAKO, TOMOFUMI, et al.
Publicado: (2015)

Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling
por: Nishiya, Naoyuki, et al.
Publicado: (2019)

DNA methylation status of REIC/Dkk-3 gene in human malignancies
por: Hayashi, Tatsuro, et al.
Publicado: (2012)

Breast Cancer Metastasis to the Stomach That Was Diagnosed after Endoscopic Submucosal Dissection
por: Kita, Masahide, et al.
Publicado: (2016)

Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers
por: Iwamoto, Takayuki, et al.
Publicado: (2017)

Effects of lifestyle and single nucleotide polymorphisms on breast cancer risk: a case–control study in Japanese women
por: Mizoo, Taeko, et al.
Publicado: (2013)

A Multicenter Study of Docetaxel at a Dose of 100 mg/m(2) in Japanese Patients with Advanced or Recurrent Breast Cancer
por: Hirata, Taizo, et al.
Publicado: (2020)

p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors
por: Yamamoto, Mitsugu, et al.
Publicado: (2014)

Cytokeratin 20 (CK20) and apomucin 1 (MUC1) expression in ampullary carcinoma: Correlation with tumor progression and prognosis
por: Kawabata, Yasunari, et al.
Publicado: (2010)

Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study
por: Shien, Tadahiko, et al.
Publicado: (2017)

Metastatic colonic and gastric polyps from breast cancer resembling hyperplastic polyps
por: Horimoto, Yoshiya, et al.
Publicado: (2018)

Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin
por: Inao, Touko, et al.
Publicado: (2018)

Lung transplantation for idiopathic multicentric Castleman disease: potential efficacy and tolerability of a humanized anti-interleukin-6 receptor monoclonal antibody
por: Tomioka, Yasuaki, et al.
Publicado: (2021)

Recurring radiation-induced angiosarcoma of the breast that was treated with paclitaxel chemotherapy: a case report
por: Suzuki, Yoko, et al.
Publicado: (2020)

YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development
por: Fujihara, Miwa, et al.
Publicado: (2021)

Effectiveness of Intraoperative Indocyanine Green Fluorescence-Navigated Surgery for Superior Mesenteric Vein Thrombosis that Developed During Treatment for Intravascular Lymphoma: A Case Report
por: Nakamoto, Hiroki, et al.
Publicado: (2021)

Impact of breast surgery in de novo stage IV breast cancer
por: Shien, Tadahiko
Publicado: (2019)

Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer
por: Suyama, Koichi, et al.
Publicado: (2017)

Different sensitivities of senescent breast cancer cells to immune cell‐mediated cytotoxicity
por: Inao, Touko, et al.
Publicado: (2019)

Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer
por: Ogiya, Rin, et al.
Publicado: (2017)

Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)
por: Masuda, Jun, et al.
Publicado: (2023)

Unmet Information Needs and Quality of Life in Young Breast Cancer Survivors in Japan
por: Miyashita, Mika, et al.
Publicado: (2015)

Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2021)

Difficult Diagnosis and Surgical Procedure for Scirrhous Gastric Cancer Complicated by Upside-Down Stomach: A Case Report
por: Nakamoto, Hiroki, et al.
Publicado: (2020)

A Benign Appendiceal-Colonic Fistula, Diagnosed and Managed Laparoscopically: A Case Report
por: Nakamoto, Hiroki, et al.
Publicado: (2020)

Survival and prognostic factors in patients undergoing pulmonary metastasectomy for lung metastases from retroperitoneal sarcoma
por: Takatsu, Fumiaki, et al.
Publicado: (2022)

Loco-regional therapy for metastatic breast cancer
por: Shien, Tadahiko, et al.
Publicado: (2020)

Splicing factors control C. elegans behavioural learning in a single neuron by producing DAF-2c receptor
por: Tomioka, Masahiro, et al.
Publicado: (2016)

A Case of Pneumothorax Required Surgical Treatment as a Complication of Paclitaxel with Bevacizumab Treatment
por: Moriya, Yumi, et al.
Publicado: (2023)

ZMIZ2 promotes the development of triple-receptor negative breast cancer
por: Zou, Xiaopan, et al.
Publicado: (2022)

Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bt4bndg1c4a9n2tqilpfko14j0